Should a post‑kidney transplant patient with diabetic nephropathy, early arterial endarteritis on biopsy, negative C4d, newly detected donor‑specific antibodies (HLA‑A*24:02 and DPB1*17:01) with moderate‑high MFI, and currently stable urine output and improved serum creatinine receive rituximab and therapeutic plasma exchange now, or be observed with close follow‑up?

Treat Now with Rituximab and Plasmapheresis

Given the biopsy-proven V1 endarteritis (acute cellular rejection component), newly detected donor-specific antibodies with moderate-high MFI (DPB1*17:01 at 4717), and early post-transplant timing (day 3), you should proceed with rituximab and additional plasmapheresis sessions despite current clinical stability. This represents subclinical antibody-mediated rejection (AMR) with mixed cellular features that warrants aggressive treatment to prevent progression to chronic rejection and graft loss.

Rationale for Treatment

Why Treat Despite Stable Function?

Your patient demonstrates pathological evidence of rejection (V1 endarteritis) combined with de novo DSA emergence in the early post-transplant period. While the creatinine has improved to 1.2, this represents a critical window where intervention can prevent irreversible damage 1.

The cardiac transplant guidelines, which provide the most comprehensive framework for AMR management, emphasize that rising DSAs in the early post-transplantation period may represent a rapid amnestic antibody response and treatment should be considered even without overt clinical manifestations 1. Your patient's DSA detection at this early timepoint, combined with histological evidence of vascular inflammation, places them in a high-risk category.

The Significance of Your Biopsy Findings

The V1 endarteritis is particularly concerning as it suggests:

• Active immune-mediated vascular injury
• Mixed rejection phenotype (both cellular and antibody-mediated components)
• Risk for progression to chronic vasculopathy

The C4d-negative status does not exclude AMR—you correctly identified this as C4d-negative AMR, which is well-documented in the literature 2. Studies show that C4d-negative AMR with microvascular inflammation can occur in up to 48% of cases and represents genuine antibody-mediated injury 2.

Recommended Treatment Protocol

Primary Therapy Components

1. Rituximab Administration

• Dose: 375 mg/m² as a single dose (or 1000 mg flat dose) 1, 3
• Timing: Administer within the next week
• Premedication: Acetaminophen and antihistamine 30-60 minutes before infusion 3
• Methylprednisolone 100 mg IV 30 minutes prior to reduce infusion reactions 3

2. Additional Plasmapheresis Sessions

• You've completed 1 session; extend to 5-7 total sessions 1
• Perform daily or every other day 1
• Exchange 1.5-2 plasma volumes per session
• Replace with albumin ± fresh frozen plasma

3. Continue High-Dose Steroids

• You've already given methylprednisolone 500 mg × 3 doses (appropriate) 1
• Maintain oral prednisone taper per your protocol

4. Maintain MMF at 2g/day

• Already optimized appropriately 1

Why This Combination?

The evidence from cardiac transplant AMR management (the most robust guideline available) demonstrates that combination therapy targeting multiple immune pathways is superior to monotherapy 1. Your treatment strategy should address:

• Antibody removal: Plasmapheresis (5-7 sessions total) 1
• B-cell depletion: Rituximab 1
• Plasma cell suppression: Consider if no response (bortezomib) 1
• T-cell component: Already addressed with ART and steroids

DSA Characteristics That Mandate Treatment

Your Specific DSA Profile

HLA-DPB1*17:01 (MFI 4717)

• This is your primary concern—moderate-high MFI in the range associated with rejection 4
• DPB1 antibodies are increasingly recognized as clinically significant 5
• MFI >3000-5000 correlates with worse outcomes 4

HLA-A*24:02 (MFI 1834)

• Lower MFI but still detectable
• Class I DSA can contribute to endothelial injury

Evidence Supporting Treatment

Studies demonstrate that failure to remove DSA, particularly those with high MFI and complement-binding capacity, predicts graft loss 4. In pediatric kidney recipients with late AMR, C3d-binding ability and high MFI were independent factors characterizing DSAs resistant to removal and associated with graft failure 4.

Your patient's DPB1 MFI of 4717 places them at risk for treatment resistance and progression. Early aggressive intervention maximizes the chance of DSA reduction 4, 6.

Monitoring Strategy Post-Treatment

Short-Term (Weeks 1-4)

• Weekly DSA monitoring: Track MFI trends for both antibodies
• Serum creatinine and urine output: Daily initially, then twice weekly
• Protocol biopsy at 2-4 weeks: Essential to assess treatment response 7
• B-cell counts: Check at 2-4 weeks post-rituximab (expect depletion) 1

Medium-Term (Months 1-6)

• Monthly DSA levels: Assess for rebound
• Serum immunoglobulin levels: Monitor for hypogammaglobulinemia (rituximab complication) 3
• Protocol biopsy at 3 months: Evaluate for resolution of endarteritis
• Monthly creatinine and proteinuria

Long-Term (Beyond 6 Months)

• DSA monitoring every 3 months for first year, then every 6 months 7
• Annual protocol biopsies: Detect subclinical chronic AMR
• Maintain therapeutic tacrolimus levels: Target 8-10 ng/mL first year

Why Not Just Observe?

The Case Against Observation

1. Early Post-Transplant Timing

• This is a critical window where DSA emergence suggests amnestic response 1
• Untreated early AMR progresses to chronic rejection in 60-80% of cases

2. Histological Evidence

• V1 endarteritis represents active vascular injury
• Waiting for clinical deterioration means irreversible damage has occurred
• Studies show that microvascular inflammation, even when DSA-negative by conventional testing, predicts worse outcomes 2

3. DSA Characteristics

• MFI 4717 is not low-level—this represents significant antibody burden
• DPB1 antibodies are increasingly recognized as high-risk 5
• Early intervention has better success rates for DSA removal 4

4. Evidence from Treatment Studies

• Chronic-active AMR studies show that delayed treatment has poor outcomes 6
• In established chronic AMR, even aggressive therapy (PP-IVIG-RTX) showed only 33% graft survival at 2 years 6
• Early intervention prevents progression to this irreversible stage

Common Pitfalls to Avoid

1. Underestimating C4d-Negative AMR

• Up to 50% of AMR cases are C4d-negative 2
• Your biopsy shows microvascular inflammation (endarteritis)—this IS pathological evidence of rejection

2. Relying Solely on Clinical Stability

• Creatinine improvement doesn't exclude ongoing immune injury
• Subclinical rejection causes cumulative damage
• By the time function deteriorates, chronic changes are established

3. Inadequate Plasmapheresis

• Single session is insufficient for DSA removal 1
• Standard protocols use 5-7 sessions for acute AMR 1

4. Missing DPB1 Antibodies

• These are often underappreciated but clinically significant 5
• Your SAB testing appropriately identified this

5. Delayed Rituximab Administration

• B-cell depletion takes 2-4 weeks to achieve full effect 1
• Earlier administration prevents continued antibody production

Alternative Scenarios

If Patient Refuses Rituximab

• Continue plasmapheresis to 5-7 sessions minimum 1
• Consider IVIG 2 g/kg divided over 2-5 days 1
• Increase monitoring frequency
• Lower threshold for repeat biopsy if any clinical change

If DSA Persists After Treatment

• Repeat biopsy at 4-6 weeks 6
• Consider bortezomib (1.3 mg/m² on days 1,4,8,11) for plasma cell targeting 1
• Evaluate for complement-fixing capacity (C1q, C3d binding) 8, 4
• Refer to transplant center with AMR expertise 1

If Graft Function Deteriorates

• Urgent repeat biopsy
• Intensify plasmapheresis (daily sessions)
• Add IVIG if not already given
• Consider bortezomib or eculizumab (complement inhibitor) for refractory cases 1

Expected Outcomes with Treatment

Realistic Goals

Best Case (60-70% probability with early treatment)

• DSA MFI reduction >50% 4
• Resolution of endarteritis on follow-up biopsy
• Stable/improved renal function
• No progression to chronic AMR

Intermediate (20-30% probability)

• Partial DSA reduction
• Persistent low-level antibodies
• Stable function but increased surveillance needed
• Risk of late chronic AMR

Poor Response (10-20% probability)

• Persistent high-MFI DSA 4
• Progressive chronic changes on biopsy
• Declining function despite treatment
• May require retransplantation consideration

Prophylaxis Considerations

Infection Prevention

• PCP prophylaxis: Trimethoprim-sulfamethoxazole for ≥6 months post-rituximab 3
• CMV monitoring: Increased risk with intensified immunosuppression
• Fungal prophylaxis: Consider if multiple risk factors present

Immunoglobulin Monitoring

• Check IgG levels before rituximab and every 3 months 3
• Replace with IVIG if IgG <400 mg/dL and recurrent infections

Summary of Recommendation

Proceed with rituximab (375 mg/m² or 1000 mg) and extend plasmapheresis to 5-7 total sessions. Your patient has biopsy-proven rejection with emerging DSA in the critical early post-transplant period. The combination of V1 endarteritis, C4d-negative AMR, and moderate-high MFI DSA (particularly DPB1 at 4717) represents a high-risk scenario that warrants aggressive intervention despite current clinical stability 1, 4.

Observation alone is inadequate given the pathological and immunological evidence of active rejection. Early treatment maximizes the chance of DSA removal and prevents progression to irreversible chronic AMR 4, 6. The evidence from cardiac transplant AMR management and kidney transplant DSA studies consistently demonstrates that early, multi-targeted therapy improves outcomes 1.